nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Topotecan—cervical cancer	0.716	1	CbGbCtD
Leflunomide—DHODH—female reproductive system—cervical cancer	0.00941	0.075	CbGeAlD
Leflunomide—DHODH—female gonad—cervical cancer	0.00856	0.0682	CbGeAlD
Leflunomide—PTK2B—decidua—cervical cancer	0.00758	0.0604	CbGeAlD
Leflunomide—PTK2B—renal system—cervical cancer	0.00744	0.0593	CbGeAlD
Leflunomide—AHR—uterine cervix—cervical cancer	0.00654	0.0521	CbGeAlD
Leflunomide—AHR—decidua—cervical cancer	0.00623	0.0497	CbGeAlD
Leflunomide—PTK2B—female reproductive system—cervical cancer	0.00596	0.0475	CbGeAlD
Leflunomide—AHR—endometrium—cervical cancer	0.00591	0.0472	CbGeAlD
Leflunomide—AHR—mammalian vulva—cervical cancer	0.00572	0.0456	CbGeAlD
Leflunomide—DHODH—lymph node—cervical cancer	0.0055	0.0439	CbGeAlD
Leflunomide—AHR—uterus—cervical cancer	0.00545	0.0435	CbGeAlD
Leflunomide—PTK2B—female gonad—cervical cancer	0.00542	0.0432	CbGeAlD
Leflunomide—PTK2B—vagina—cervical cancer	0.00539	0.043	CbGeAlD
Leflunomide—Pelvic pain—Topotecan—cervical cancer	0.00533	0.0484	CcSEcCtD
Leflunomide—AHR—female reproductive system—cervical cancer	0.0049	0.0391	CbGeAlD
Leflunomide—Neuralgia—Topotecan—cervical cancer	0.00467	0.0424	CcSEcCtD
Leflunomide—Interstitial lung disease—Topotecan—cervical cancer	0.00458	0.0416	CcSEcCtD
Leflunomide—AHR—female gonad—cervical cancer	0.00446	0.0355	CbGeAlD
Leflunomide—AHR—vagina—cervical cancer	0.00443	0.0353	CbGeAlD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—PIAS3—cervical cancer	0.00379	0.0787	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—PIAS3—cervical cancer	0.0036	0.0748	CbGpPWpGaD
Leflunomide—PTK2B—lymph node—cervical cancer	0.00349	0.0278	CbGeAlD
Leflunomide—Bone pain—Topotecan—cervical cancer	0.00339	0.0307	CcSEcCtD
Leflunomide—Colitis—Topotecan—cervical cancer	0.00311	0.0283	CcSEcCtD
Leflunomide—Rash maculo-papular—Topotecan—cervical cancer	0.00295	0.0268	CcSEcCtD
Leflunomide—Neoplasm—Topotecan—cervical cancer	0.00293	0.0266	CcSEcCtD
Leflunomide—AHR—lymph node—cervical cancer	0.00287	0.0228	CbGeAlD
Leflunomide—Sepsis—Topotecan—cervical cancer	0.00282	0.0255	CcSEcCtD
Leflunomide—ABCG2—uterine cervix—cervical cancer	0.00254	0.0202	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.00247	0.0513	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—UBE3A—cervical cancer	0.00244	0.0507	CbGpPWpGaD
Leflunomide—Anaphylactoid reaction—Topotecan—cervical cancer	0.00243	0.0221	CcSEcCtD
Leflunomide—ABCG2—decidua—cervical cancer	0.00242	0.0193	CbGeAlD
Leflunomide—ABCG2—endometrium—cervical cancer	0.00229	0.0183	CbGeAlD
Leflunomide—CYP1A2—renal system—cervical cancer	0.00228	0.0182	CbGeAlD
Leflunomide—ABCG2—mammalian vulva—cervical cancer	0.00222	0.0177	CbGeAlD
Leflunomide—Cramp muscle—Topotecan—cervical cancer	0.00212	0.0192	CcSEcCtD
Leflunomide—ABCG2—uterus—cervical cancer	0.00211	0.0169	CbGeAlD
Leflunomide—Pancytopenia—Topotecan—cervical cancer	0.00193	0.0175	CcSEcCtD
Leflunomide—Neutropenia—Topotecan—cervical cancer	0.0019	0.0173	CcSEcCtD
Leflunomide—Pneumonia—Topotecan—cervical cancer	0.00183	0.0166	CcSEcCtD
Leflunomide—Infestation NOS—Topotecan—cervical cancer	0.00181	0.0165	CcSEcCtD
Leflunomide—Infestation—Topotecan—cervical cancer	0.00181	0.0165	CcSEcCtD
Leflunomide—Neuropathy peripheral—Topotecan—cervical cancer	0.00178	0.0161	CcSEcCtD
Leflunomide—Stomatitis—Topotecan—cervical cancer	0.00177	0.0161	CcSEcCtD
Leflunomide—CYP2C9—female reproductive system—cervical cancer	0.00174	0.0138	CbGeAlD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PIAS3—cervical cancer	0.00173	0.036	CbGpPWpGaD
Leflunomide—ABCG2—female gonad—cervical cancer	0.00173	0.0138	CbGeAlD
Leflunomide—ABCG2—vagina—cervical cancer	0.00172	0.0137	CbGeAlD
Leflunomide—Hepatobiliary disease—Topotecan—cervical cancer	0.00172	0.0156	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—UBE3A—cervical cancer	0.00171	0.0356	CbGpPWpGaD
Leflunomide—Epistaxis—Topotecan—cervical cancer	0.00171	0.0155	CcSEcCtD
Leflunomide—Haemoglobin—Topotecan—cervical cancer	0.00164	0.0149	CcSEcCtD
Leflunomide—Rhinitis—Topotecan—cervical cancer	0.00163	0.0148	CcSEcCtD
Leflunomide—Haemorrhage—Topotecan—cervical cancer	0.00163	0.0148	CcSEcCtD
Leflunomide—Pharyngitis—Topotecan—cervical cancer	0.00162	0.0147	CcSEcCtD
Leflunomide—Immune system disorder—Topotecan—cervical cancer	0.00147	0.0134	CcSEcCtD
Leflunomide—Mediastinal disorder—Topotecan—cervical cancer	0.00147	0.0133	CcSEcCtD
Leflunomide—Chills—Topotecan—cervical cancer	0.00146	0.0133	CcSEcCtD
Leflunomide—Alopecia—Topotecan—cervical cancer	0.00144	0.0131	CcSEcCtD
Leflunomide—Malnutrition—Topotecan—cervical cancer	0.00142	0.0129	CcSEcCtD
Leflunomide—Back pain—Topotecan—cervical cancer	0.00137	0.0124	CcSEcCtD
Leflunomide—Muscle spasms—Topotecan—cervical cancer	0.00136	0.0124	CcSEcCtD
Leflunomide—Ill-defined disorder—Topotecan—cervical cancer	0.00132	0.0119	CcSEcCtD
Leflunomide—Anaemia—Topotecan—cervical cancer	0.00131	0.0119	CcSEcCtD
Leflunomide—Angioedema—Topotecan—cervical cancer	0.0013	0.0118	CcSEcCtD
Leflunomide—Malaise—Topotecan—cervical cancer	0.00128	0.0116	CcSEcCtD
Leflunomide—Leukopenia—Topotecan—cervical cancer	0.00127	0.0115	CcSEcCtD
Leflunomide—Cough—Topotecan—cervical cancer	0.00124	0.0112	CcSEcCtD
Leflunomide—Chest pain—Topotecan—cervical cancer	0.00121	0.011	CcSEcCtD
Leflunomide—Arthralgia—Topotecan—cervical cancer	0.00121	0.011	CcSEcCtD
Leflunomide—Myalgia—Topotecan—cervical cancer	0.00121	0.011	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.0012	0.0109	CcSEcCtD
Leflunomide—Discomfort—Topotecan—cervical cancer	0.00119	0.0108	CcSEcCtD
Leflunomide—Anaphylactic shock—Topotecan—cervical cancer	0.00116	0.0105	CcSEcCtD
Leflunomide—Infection—Topotecan—cervical cancer	0.00115	0.0104	CcSEcCtD
Leflunomide—Nervous system disorder—Topotecan—cervical cancer	0.00114	0.0103	CcSEcCtD
Leflunomide—Thrombocytopenia—Topotecan—cervical cancer	0.00113	0.0103	CcSEcCtD
Leflunomide—Skin disorder—Topotecan—cervical cancer	0.00112	0.0102	CcSEcCtD
Leflunomide—Hyperhidrosis—Topotecan—cervical cancer	0.00112	0.0102	CcSEcCtD
Leflunomide—ABCG2—lymph node—cervical cancer	0.00111	0.00886	CbGeAlD
Leflunomide—Anorexia—Topotecan—cervical cancer	0.0011	0.01	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00105	0.00957	CcSEcCtD
Leflunomide—Paraesthesia—Topotecan—cervical cancer	0.00104	0.00943	CcSEcCtD
Leflunomide—Dyspnoea—Topotecan—cervical cancer	0.00103	0.00936	CcSEcCtD
Leflunomide—ABCG2—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00103	0.0214	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.00102	0.0212	CbGpPWpGaD
Leflunomide—Dyspepsia—Topotecan—cervical cancer	0.00102	0.00924	CcSEcCtD
Leflunomide—Decreased appetite—Topotecan—cervical cancer	0.00101	0.00913	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Topotecan—cervical cancer	0.000999	0.00907	CcSEcCtD
Leflunomide—Fatigue—Topotecan—cervical cancer	0.000998	0.00905	CcSEcCtD
Leflunomide—Pain—Topotecan—cervical cancer	0.00099	0.00898	CcSEcCtD
Leflunomide—Constipation—Topotecan—cervical cancer	0.00099	0.00898	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.00098	0.0204	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.00098	0.0204	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—STAT3—cervical cancer	0.000964	0.02	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—FGFR3—cervical cancer	0.000958	0.0199	CbGpPWpGaD
Leflunomide—Feeling abnormal—Topotecan—cervical cancer	0.000954	0.00865	CcSEcCtD
Leflunomide—Gastrointestinal pain—Topotecan—cervical cancer	0.000947	0.00859	CcSEcCtD
Leflunomide—Urticaria—Topotecan—cervical cancer	0.00092	0.00834	CcSEcCtD
Leflunomide—Abdominal pain—Topotecan—cervical cancer	0.000915	0.0083	CcSEcCtD
Leflunomide—Body temperature increased—Topotecan—cervical cancer	0.000915	0.0083	CcSEcCtD
Leflunomide—Hypersensitivity—Topotecan—cervical cancer	0.000853	0.00774	CcSEcCtD
Leflunomide—Asthenia—Topotecan—cervical cancer	0.00083	0.00754	CcSEcCtD
Leflunomide—Pruritus—Topotecan—cervical cancer	0.000819	0.00743	CcSEcCtD
Leflunomide—Diarrhoea—Topotecan—cervical cancer	0.000792	0.00719	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—CD8A—cervical cancer	0.000778	0.0162	CbGpPWpGaD
Leflunomide—Dizziness—Topotecan—cervical cancer	0.000765	0.00695	CcSEcCtD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—STAT3—cervical cancer	0.000754	0.0157	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000746	0.0155	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CASP8—cervical cancer	0.000743	0.0154	CbGpPWpGaD
Leflunomide—Vomiting—Topotecan—cervical cancer	0.000736	0.00668	CcSEcCtD
Leflunomide—Rash—Topotecan—cervical cancer	0.00073	0.00662	CcSEcCtD
Leflunomide—Dermatitis—Topotecan—cervical cancer	0.000729	0.00662	CcSEcCtD
Leflunomide—Headache—Topotecan—cervical cancer	0.000725	0.00658	CcSEcCtD
Leflunomide—PTK2B—Integrins in angiogenesis—CASP8—cervical cancer	0.000724	0.015	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000722	0.015	CbGpPWpGaD
Leflunomide—Nausea—Topotecan—cervical cancer	0.000688	0.00624	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000655	0.0136	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000637	0.0132	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—STAT3—cervical cancer	0.000637	0.0132	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—UBE3A—cervical cancer	0.000614	0.0128	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—MTOR—cervical cancer	0.000581	0.0121	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CTNNB1—cervical cancer	0.000542	0.0113	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—CASP3—cervical cancer	0.000541	0.0112	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MTOR—cervical cancer	0.000539	0.0112	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CTNNB1—cervical cancer	0.000539	0.0112	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CASP3—cervical cancer	0.000534	0.0111	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—STAT3—cervical cancer	0.000521	0.0108	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—STAT3—cervical cancer	0.000521	0.0108	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CA9—cervical cancer	0.000502	0.0104	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—cervical cancer	0.000497	0.0103	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000496	0.0103	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000478	0.00994	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MTOR—cervical cancer	0.000473	0.00984	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CD4—cervical cancer	0.000472	0.00982	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—STAT3—cervical cancer	0.00047	0.00976	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—STAT3—cervical cancer	0.000449	0.00933	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD4—cervical cancer	0.000447	0.00929	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DPB1—cervical cancer	0.000431	0.00895	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000413	0.00859	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—cervical cancer	0.000413	0.00859	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—MTOR—cervical cancer	0.00039	0.0081	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000379	0.00787	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—MTOR—cervical cancer	0.000368	0.00765	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—STAT3—cervical cancer	0.000366	0.0076	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.000346	0.00718	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—cervical cancer	0.000343	0.00712	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HLA-DQB1—cervical cancer	0.000336	0.00699	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—STAT3—cervical cancer	0.000326	0.00679	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—CTNNB1—cervical cancer	0.000326	0.00678	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000318	0.00661	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—MTOR—cervical cancer	0.000307	0.00639	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—STAT3—cervical cancer	0.000299	0.00622	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—CTNNB1—cervical cancer	0.000296	0.00615	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CASP3—cervical cancer	0.000283	0.00588	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.00028	0.00582	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—cervical cancer	0.000274	0.00569	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CTNNB1—cervical cancer	0.000273	0.00567	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000272	0.00565	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—cervical cancer	0.000253	0.00526	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—STAT3—cervical cancer	0.000238	0.00494	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—UBE3A—cervical cancer	0.000236	0.0049	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.000216	0.00449	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—MTHFR—cervical cancer	0.000204	0.00423	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TAAR6—cervical cancer	0.000198	0.00412	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000197	0.00408	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—WNT2—cervical cancer	0.000155	0.00321	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DPB1—cervical cancer	0.000141	0.00292	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—cervical cancer	0.00014	0.0029	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKAP13—cervical cancer	0.000136	0.00282	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—WNT5A—cervical cancer	0.000117	0.00244	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DQB1—cervical cancer	0.00011	0.00228	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000108	0.00224	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000108	0.00224	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—cervical cancer	0.000103	0.00213	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGFR3—cervical cancer	8.39e-05	0.00174	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH2—cervical cancer	8.22e-05	0.00171	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CA9—cervical cancer	8.12e-05	0.00169	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CASP8—cervical cancer	7.17e-05	0.00149	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HES1—cervical cancer	6.74e-05	0.0014	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—cervical cancer	5.91e-05	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MTOR—cervical cancer	5.9e-05	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—cervical cancer	5.89e-05	0.00122	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGFR3—cervical cancer	5.42e-05	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—cervical cancer	5.23e-05	0.00109	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH1—cervical cancer	5.09e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—cervical cancer	4.56e-05	0.000948	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—cervical cancer	4.14e-05	0.000861	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA9—cervical cancer	4.1e-05	0.000852	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MTOR—cervical cancer	3.81e-05	0.000793	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—cervical cancer	3.51e-05	0.000729	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CA9—cervical cancer	3.5e-05	0.000728	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—cervical cancer	3.38e-05	0.000703	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—cervical cancer	3.29e-05	0.000685	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—cervical cancer	2.95e-05	0.000613	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—cervical cancer	2.68e-05	0.000557	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—cervical cancer	2.25e-05	0.000467	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—cervical cancer	1.66e-05	0.000346	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—cervical cancer	1.42e-05	0.000295	CbGpPWpGaD
